Predicted failure of common Mpox PCR testing on a recent DRC clade I variant: Persistent genomic surveillance is critically important for accurate diagnostics

Dawn Gratalo; Valerie J. Morley; Ben Oppenheim; Casandra W. Philipson; Sarah Rush; Swati Sureka; Mitchell I. Wolfe; Birgitte B. Simen

doi:10.1101/2024.07.22.24310820

Abstract

Pathogens can rapidly evolve to evade detection via existing diagnostic testing capabilities, creating blind spots for health care and security systems. Persistent genomic surveillance of pathogens can help identify and address these gaps. Here, we present a case study of a new lineage of Monkeypox virus Clade I that emerged during an outbreak in the Democratic Republic of the Congo, in which a genomic deletion allowed the virus to evade detection by current diagnostic assays. We rapidly developed and validated an updated assay. Availability of pathogen genomic data is a critical input, and often a bottleneck, to response efforts.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was funded by Ginkgo Bioworks

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes